Table 5.

Screening for Vertebral Osteoporosis in 10,000 Men ≥50 Years of Age: Vertebral Fracture Outcomes by 5-Year Intervals

Age Group (years)50–5455–5960–6465–6970–7475–7980–8485–89
Sensitivity0.2880.4670.8780.8230.710.8390.8510.751
Specificity0.8980.6370.6710.6180.4970.4720.310.227
Base/Case Assumptions per 10,000
    5-yr risk of vertebral fracture*350.0060.0080.0100.0130.0170.0210.0210.014
    Osteoporosis risk300.0500.0510.0390.0260.0350.0510.0550.025
    Relative risk for vertebra fracture w/Rx340.520.520.520.520.520.520.520.52
    Adherence to Rx, proportion340.70.70.70.70.70.70.70.7
Results, per 10,000 men (n)
    Predicted cases of osteoporosis (n)501.6513.1394.2263.8345.0508.6549.7248.3
    MORES TP144.5239.6346.1217.1245.0426.7467.8186.5
    MORES FN357.2273.548.146.7100.181.981.961.8
    MORES TN8529.56043.16445.56017.04798.54480.02929.62213.6
    MORES FP968.83443.73160.33719.24856.55011.56520.77538.1
    Referred for DXA (TP + FP)1113.33683.43506.43936.35101.45438.26988.57724.5
Predicted Vertebral Fx: MORES/DXA screening (n)
    TP with Rx0.601.242.181.872.815.816.521.67
    FN with no Rx2.252.130.460.611.731.681.720.83
    Total Fx with Rx after screening2.853.372.642.484.547.498.242.51
    Unscreened, untreated3.164.003.743.435.9710.4311.543.35
NNS MORES: DXA36415866317541513583185121189134
NNT MORES: DXA1641818357279243174167294
Universal DXA screening (n)
    Fracture with Rx2.102.662.492.283.966.927.662.23
    Fracture with no Rx3.164.003.743.435.9710.4311.543.35
NNS universal DXA94187437794986784987285525798880
NNT universal DXA473382314229173146142221
  • * Mean, 10 years risk across age groups ÷ 2.

  • MORES, Male Osteoporosis Risk Estimation Score; Rx, bisphosphonate therapy; TP, true positives; FN, false negatives; TN, true negatives; FP, false positives; DXA, done densitometry; NNS, number needed to screen to prevent one additional vertebral fracture; NNT, number needed to treat to prevent one additional vertebral fracture; Fx, fracture.